Schürer M, Baumann M, Beyreuther E, Brüchner K, Enghardt W, Kaluza M, Karsch  L, Laschinsky L, Leßmann E, Nicolai M, Oppelt M, Reuter M, Richter C, Sävert A, Schnell M, Woithe J, Pawelke J (2012) Irradiation system for pre-clinical studies with  laser accelerated electrons. Biomed Tech 57: 62-65

Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, Baumann M, Steinbach J, Rodemann HP (2012) Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in  vitro. Strahlenther Onkol 188: 823-832

Gurtner K, Hessel F, Eicheler W, Dörfler A, Zips D, Heider KH, Krause M, Baumann M (2012) Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. Radiother Oncol 102: 444-449

Eke I, Deuse Y, Hehlgans S, Krause M, Baumann M, Shevchenko A, Cordes N (2012). beta1 integrin-FAK-Cortactin signaling essential for head and neck cancer radioresistance. J Clin Invest 122: 1529-1540

Yaromina A, Krause M, Baumann M (2012) Individualization of cancer treatment from radiotherapy perspective. Mol Oncol 6: 211-221

Singer A, Deuse Y, Koch U, Hölscher T, Pfitzmann D, Jakob C, Hehlgans S, Baretton GB, Rentsch A, Baumann M, Muders MH, Krause M (2012) Impact of the adaptor protein GIPC1/Synectin on radioresistance and survival after irradiation of prostate cancer. Strahlenther Onkol 188: 1125-1132

Baumann M, Zips D, Krause M (2012) Experimentelle Tumortherapie. Strahlenther Onkol 188 Suppl 3: 291-294.

Kast K, Krause M, Schuler M, Friedrich K, Thamm B, Bier A, Distler W, Krüger S (2012) Late onset Li-Fraumeni syndrome with bilateral breast cancer and other malignancies: case report and review of the literature. BMC Cancer 12: 21

Mansour W, Bogdanova N, Kasten-Pisula U, Rieckmann T, Koecher S,  Borgmann K, Baumann M, Krause M, Petersen C, Hu H, Gatti RA, Dikomey E, Dörk T, Dahm-Daphi J (2012) Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. Radiother Oncol 106: 147-154

Andreassen CN, Barnett GC, Langendijk JA, Alsner J, De Ruysscher D, Krause M, Bentzen SM, Haviland JS, Griffin C, Poortmans P and Yarnold J on behalf of the ESTRO GENEPI network (2012) Conducting radiogenomic research – do not forget careful consideration of the clinical data. Radiother Oncol 105: 337-340

Yaromina A, Meyer S, Fabian C, Zaleska K, Sattler UG, Kunz-Schughart LA, Mueller-Klieser W, Zips D, Baumann M (2012) Effects of three modifiers of glycolysis on ATP, lactate, hypoxia, and growth in human tumor cell lines in vivo. Strahlenther Onkol 188: 431-437

Helbig L, Yaromina A, Sriramareddy SN, Böke S, Koi L, Thames HD, Baumann M, Zips D (2012) Prognostic value of HIF-1α expression during fractionated irradiation. Strahlenther Onkol 188: 1031-1037

Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M (2012) Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 22:151-174

Bayer C, Kielow A, Schilling D, Maftei CA, Zips D, Yaromina A, Baumann M, Molls M, Multhoff G (2012) Monitoring PAI-1 and VEGF levels in 6 human squamous cell carcinoma xenografts during fractionated irradiation. Int J Radiat Oncol Biol Phys 84: e409-e417

Laschinsky L, Baumann M, Beyreuther E, Enghardt W, Kaluza M, Karsch L, Lessmann E, Naumburger D, Nicolai M, Richter C, Sauerbrey R, Schlenvoigt HP, Pawelke J. (2012) Radiobiological effectiveness of laser accelerated electrons in comparison to electron beams from a conventional linear accelerator. J Radiat Res. 53: 395-403

Mazzeo E, Hehlgans S, Valentini V, Baumann M, Cordes N. (2012) The impact of cell-cell contact, e-cadherin and EGF receptor on the cellular radiosensitivity of A431 cancer cells. Radiat Res 178: 224-233

Abramyuk A, Appold S, Zöphel K, Hietschold V, Baumann M, Abolmaali N. (2012) Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy - A retrospective study. Lung Cancer 78: 148-152

Peickert S, Waurig J, Dittfeld C, Dietrich A, Garbe Y, Kabus L, Baumann M, Grade M, Ried T, Kunz-Schughart LA. (2012) Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo. Lab Invest 92: 1607-1622

Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP (2012) Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 30: 2788-2797

Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, Baumann M, Steinbach J, Rodemann HP (2012). Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro. Strahlenther Onkol 188: 823-832

Ingargiola M, Dittfeld C, Runge R, Zenker M, Heldt JM, Steinbach J, Cordes N, Baumann M, Kotzerke J, Kunz-Schughart LA (2012) Flow cytometric cell-based assay to preselect antibody constructs for radionuclide conjugation. Cytometry A 81: 865-873

Zips D, Zöphel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S, Steinbach J, Kotzerke J, Baumann M (2012). Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 105: 21-28